Market Intelligence, Clinical Progress, and High-Purity Reagents for Isoform-Selective Calcineurin Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PPP3CB phosphatase drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPP3CB Recombinant Protein (Catalytic Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View PPP3CB Products |
| Isoform Panel | PPP3CA (Alpha Isoform) Recombinant Protein For selectivity counter-screening. Sequence Verified. |
View PPP3CA Products |
| Complex Partner | PPP3R1 (Calcineurin B) Recombinant Protein Regulatory subunit required for phosphatase activity reconstitution. |
View PPP3R1 Products |
| Gene Delivery | PPP3CB Lentivirus / Promise-ORF Full-length ORF for stable cell line generation in neuronal/cardiac models. |
View PPP3CB Products |
| Research Ab | Anti-PPP3CB Monoclonal Antibody For Western blot and IP validation. |
View PPP3CB Products |
| Validator | PPP3CB siRNA Set (3 unique sequences) For knockdown specificity verification. |
View PPP3CB Products |
| Substrate Control | NFATC1 Recombinant Protein Canonical downstream substrate for activity assays. |
View NFATC1 Products |
| Immunophilin Co-factor | FKBP1A Recombinant Protein Required for immunosuppressant ternary complex formation. |
View FKBP1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PPP3CB vs PPP3CA) | Human PPP3CB and PPP3CA proteins available as matched pair with >95% purity; identical tags and expression systems for valid side-by-side kinetics |
| Complex-dependent Activity & Stability | PPP3R1 regulatory subunit provided for heterodimer reconstitution; verified by co-migration in native PAGE; high-purity soluble catalytic domain |
| Phosphatase Activity Standardization | Theoretical specific activity calculated; protein purity verified by Mass Spec (expected MW: 59.8 kDa) |
| Cellular Permeability Validation | Ready-to-use Lentivirus particles for stable overexpression in HEK293 and SH-SY5Y neuronal models |
| Assay Controls (Antibody & siRNA) | Sequence-confirmed Benchmark Antibodies and validated siRNA sets included for assay standardization and genetic specificity checks |
Live PPP3CB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Isoform Selectivity Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The calcineurin inhibitor market is undergoing a paradigm shift from broad immunosuppression toward isoform-selective modulation. While first-generation drugs (tacrolimus, cyclosporine) target the catalytic center non-selectively and carry risks of nephrotoxicity and neurotoxicity, next-generation R&D aims to exploit expression pattern differences: PPP3CB is enriched in neural and cardiac tissues versus PPP3CA's immune cell dominance. This opens therapeutic windows for neurodegenerative diseases (Alzheimer's, Parkinson's), cardiac hypertrophy, and localized immune responses without systemic immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Isoform-selective) | Novartis, Biogen, Academic Consortia; Astellas (Legacy CNI) | Alzheimer's Disease, Cardiac Hypertrophy, Organ Transplant, Autoimmune | PPP3CB/PPP3CA Dual-Axis Selectivity Panel (Need matched ortholog proteins) |
| Peptide / Protein Inhibitors | University Research Groups, Academic Consortia | Neuroprotection, Cardiac Hypertrophy | Complex Stability Assay (Need PPP3R1 heterodimer) |
| Targeted Protein Degraders (PROTACs) | Emerging Biotechs | Refractory Immune Disorders | Ternary Complex Validation (Need pure Target + Ligase) |
| Allosteric Modulators | Early Stage Biotech | Autoimmune (Targeted) | Conformational Binding Assay (Need full-length native protein) |